BlossomHill Therapeutics reported second quarter 2026 financial results highlighting advances in its oncology pipeline, including full compensation of an upsized $168.3 million IPO and FDA Fast Track designation for BH-30643 regarding NSCLC.
BlossomHill Therapeutics reported second quarter 2026 financial results highlighting advances in its oncology pipeline, including full compensation of an upsized $168.3 million IPO and FDA Fast Track designation for BH-30643 regarding NSCLC.